Iovance Biotherapeutics Inc (STU:2LB)
€ 10.415 0.26 (2.56%) Market Cap: 3.20 Bil Enterprise Value: 2.89 Bil PE Ratio: 0 PB Ratio: 4.43 GF Score: 39/100

Q1 2020 Iovance Biotherapeutics Inc Earnings Call Transcript

May 05, 2020 / 08:30PM GMT
Release Date Price: €29.97 (+4.83%)
Operator

Good afternoon. And welcome to Iovance First Quarter 2020 Financial Results Conference Call. (Operator Instructions) Please be advised that this call consists of a recording of prepared remarks, followed by a live question-and-answer session.

Now I would like to turn the call over to Sara Pellegrino, Vice President, Investor and Public Relations at Iovance. Please go ahead.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you, Howard. Good afternoon, everyone. And thank you for joining us. Speaking on the call today, we have Maria Fardis, our President and Chief Executive Officer; Friedrich Finckenstein, our Chief Medical Officer; and Tim Morris, Chief Financial Officer. This afternoon, we issued a press release that can be found on our website at iovance.com, which includes the financial results for the first quarter ended on March 31, 2020, as well as a corporate update.

Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot